Academic Research

  • Understand the heterogenous nature of disease biology with an enhanced mechanistic understanding of pathology and interventions.

  • Translate your basic research findings in pathophysiology to discover new drug targets.

  • Discover novel disease biomarkers by taking a mechanistic approach to disease biology.

preclinical drug discovery

Discovery/Preclinical

  • Validate which disease pathways are interrupted by your therapy. Perhaps more importantly - which are not. Discover new targets to grow your portfolio of assets.

  • Was a drug program a sunk cost for you? Find alternative therapeutic areas or sub-populations where your failed assets may be more effective.

  • Rank and compare ROI for your pipeline’s assets by probability of clinical success and gain leverage in your out licensing agreements.

  • Compare how your drug target compares with your competitors marketed in developing drugs.

human clinical trials

Phase I

  • Establish the most safe and effective dose for your expansion cohort/phase. Perform simulations to support your dosing rationale.

  • Predict off-target effects by evaluating your target’s overlap with other physiological pathways.

  • Simulate the effect of modulating multiple pathways simultaneously for your combination therapies.

Solutions at Every Phase of Drug Development

clinical efficacy

Phase II

  • Understand more about your therapy’s mechanism of action than you ever thought possible by understand the causal mechanisms of efficacy.

  • Accurately stratify patients to find the right subgroups to meet Phase II endpoints.

  • Identify & validate new biomarkers as well as untangle correlative biomarkers from causal biomarkers.

  • Predict protein concentrations to understand the extent to which protein concentrations are affected upstream/downstream of your target.

patient stratification

Phase III

  • Discover which demographics and patient characteristics are co-variates.

  • Target the right population to reduce the number of patients required to meet efficacy endpoints.

post-market diagnostics

Phase IV/Post-Market

  • Simulate on a single-patient level to optimize dose and regimen.

  • Identify biomarkers to be developed into diagnostics.